William Blair Analysts Lower Earnings Estimates for DexCom

DexCom, Inc. (NASDAQ:DXCM) – Investment analysts at William Blair dropped their Q2 2025 earnings per share (EPS) estimates for shares of DexCom in a report released on Monday, May 5th. William Blair analyst M. Andrew now anticipates that the medical device company will post earnings per share of $0.46 for the quarter, down from their previous estimate of $0.47. The consensus estimate for DexCom’s current full-year earnings is $2.03 per share. William Blair also issued estimates for DexCom’s Q3 2025 earnings at $0.60 EPS, Q4 2025 earnings at $0.66 EPS, FY2025 earnings at $2.04 EPS, Q1 2026 earnings at $0.54 EPS, Q2 2026 earnings at $0.60 EPS, Q3 2026 earnings at $0.65 EPS, Q4 2026 earnings at $0.74 EPS and FY2026 earnings at $2.53 EPS.

Several other analysts have also commented on DXCM. Piper Sandler dropped their price target on shares of DexCom from $100.00 to $90.00 and set an “overweight” rating on the stock in a research report on Friday, May 2nd. Redburn Atlantic upgraded DexCom from a “neutral” rating to a “buy” rating and lifted their price target for the company from $85.00 to $115.00 in a research note on Monday, February 3rd. Morgan Stanley increased their price target on DexCom from $75.00 to $82.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Barclays upped their target price on DexCom from $90.00 to $93.00 and gave the stock an “equal weight” rating in a research note on Monday. Finally, Citigroup lifted their price target on shares of DexCom from $101.00 to $104.00 and gave the company a “buy” rating in a research note on Tuesday, March 4th. Five research analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average price target of $98.11.

DexCom Price Performance

Shares of NASDAQ DXCM opened at $81.62 on Tuesday. The company has a debt-to-equity ratio of 0.59, a current ratio of 1.47 and a quick ratio of 1.28. The stock has a market capitalization of $32.00 billion, a price-to-earnings ratio of 57.07, a PEG ratio of 2.30 and a beta of 1.43. The firm’s 50 day simple moving average is $71.15 and its 200-day simple moving average is $76.96. DexCom has a 12 month low of $57.52 and a 12 month high of $132.26.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, May 1st. The medical device company reported $0.32 EPS for the quarter, missing the consensus estimate of $0.33 by ($0.01). DexCom had a return on equity of 30.14% and a net margin of 14.29%. The company had revenue of $1.04 billion for the quarter, compared to analyst estimates of $1.02 billion. During the same period last year, the business earned $0.32 earnings per share. The firm’s revenue was up 12.5% on a year-over-year basis.

Hedge Funds Weigh In On DexCom

A number of institutional investors and hedge funds have recently made changes to their positions in the stock. Versant Capital Management Inc purchased a new stake in shares of DexCom during the 4th quarter worth $25,000. Private Trust Co. NA lifted its holdings in DexCom by 266.3% during the 4th quarter. Private Trust Co. NA now owns 337 shares of the medical device company’s stock worth $26,000 after buying an additional 245 shares during the last quarter. Golden State Wealth Management LLC lifted its holdings in DexCom by 211.2% during the 1st quarter. Golden State Wealth Management LLC now owns 389 shares of the medical device company’s stock worth $27,000 after buying an additional 264 shares during the last quarter. Optiver Holding B.V. acquired a new position in shares of DexCom during the 4th quarter worth about $33,000. Finally, TD Private Client Wealth LLC increased its holdings in shares of DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock valued at $34,000 after acquiring an additional 167 shares during the last quarter. 97.75% of the stock is owned by institutional investors and hedge funds.

Insider Activity

In related news, CEO Kevin R. Sayer sold 32,498 shares of DexCom stock in a transaction that occurred on Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $2,287,209.24. Following the completion of the transaction, the chief executive officer now owns 372,029 shares in the company, valued at approximately $26,183,401.02. The trade was a 8.03 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, EVP Michael Jon Brown sold 13,000 shares of the business’s stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $70.38, for a total transaction of $914,940.00. Following the completion of the transaction, the executive vice president now owns 105,602 shares of the company’s stock, valued at approximately $7,432,268.76. This trade represents a 10.96 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 66,926 shares of company stock valued at $4,734,384. Company insiders own 0.32% of the company’s stock.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.